Jennifer Davies

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Christopher Butler, Richard Hobbs, Oghenekome Gbinigie et al. · The Lancet · 2022 · 406 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +7

Non-fungible tokens: The missing ingredient for sustainable supply chains in the metaverse age?

Jennifer Davies, Hossein Sharifi, Andrew C. Lyons et al. · Transportation Research Part E Logistics and Transportation Review · 2024 · 61 citations · Full text

Management, Strategic Management, Supply Chain Management +17

Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial

Christopher Butler, Richard Hobbs, Oghenekome Gbinigie et al. · SSRN Electronic Journal · 2022 · 52 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +17

A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment

Jennifer Davies, Emil Carlsson, Angela Midgley et al. · Lara D. Veeken · 2020 · 49 citations · Full text

Medicine, Nephrology, Proteomics +16

Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment

Jennifer Davies, Angela Midgley, Emil Carlsson et al. · RMD Open · 2020 · 40 citations · Full text

Medicine, Immunology, Nephrology +17